Quick Answer
Lactobacillus Casei Sleep Quality Randomized Trial has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: Among these complaints, CKD-associated pruritus is particularly difficult to manage, since it is known to be multifactorial [].
Key Takeaways
- 01Among these complaints, CKD-associated pruritus is particularly difficult to manage, since it is known to be multifactorial []. [Hung Kuo-Chin (2026)]
- 02However, existing treatments for CKD-associated pruritus and sleep disturbance are frequently suboptimal and with variable efficacy. [Hung Kuo-Chin (2026)]
- 03In a separate randomized, open-label study of patients receiving hemodialysis, LCR35, a form of freeze-dried, supplementation was associated with improvements in global Pittsburgh Sleep Quality Index (PSQI) scores and sleep duration, alterations in gut microbiota, and lower indoxyl sulfate (IS) concentrations []. [Hung Kuo-Chin (2026)]
- 041 2 3 4 5 6 7 8 9 The symptom burden of chronic kidney disease (CKD) is heterogeneous and frequently under-recognized [,,]. [Hung Kuo-Chin (2026)]
The current Migaku evidence database contains 1 reusable source document for Lactobacillus Casei Sleep Quality Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation.
- Among these complaints, CKD-associated pruritus is particularly difficult to manage, since it is known to be multifactorial []. [Hung Kuo-Chin (2026); evidence level 2]
- However, existing treatments for CKD-associated pruritus and sleep disturbance are frequently suboptimal and with variable efficacy. [Hung Kuo-Chin (2026); evidence level 2]
- In a separate randomized, open-label study of patients receiving hemodialysis, LCR35, a form of freeze-dried, supplementation was associated with improvements in global Pittsburgh Sleep Quality Index (PSQI) scores and sleep duration, alterations in gut microbiota, and lower indoxyl sulfate (IS) concentrations []. [Hung Kuo-Chin (2026); evidence level 2]
- 1 2 3 4 5 6 7 8 9 The symptom burden of chronic kidney disease (CKD) is heterogeneous and frequently under-recognized [,,]. [Hung Kuo-Chin (2026); evidence level 2]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources